Hepacure

Peptide Therapies Targeting Fibrosis in Fatty Liver Disease

Active Pre-Seed Startup Israel Founded 2024-07

Hepacure Pharma is developing a novel peptide therapy targeting fatty liver diseases, particularly non-alcoholic fatty liver disease (NAFLD). NAFLD encompasses conditions marked by excess fat in the liver, increasing the risk of serious health issues like diabetes and kidney disease. Advanced NAFLD forms, such as non-alcoholic steatohepatitis (NASH), lead t…